235980.KQ
MedPacto, Inc. [235980.KQ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
235980.KQ Stock Summary
Top 10 Correlated ETFs
235980.KQ
Top 10 Correlated Stocks
235980.KQ
In the News
235980.KQ Financial details
Company Rating
-
Market Cap
388.76B
Income
-35.32B
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
61
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-3.8
Forward P/E
-
PEG
-32.99
P/S
-
P/B
30.83
P/C
-
P/FCF
-8534.79
Quick Ratio
0.73
Current Ratio
1.15
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.47K
EPS next Y
-
EPS next Q
-
EPS this Y
14.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
39.14%
-
-
-
-
SMA20
16.62%
SMA50
18.64%
SMA100
-19.06%
Inst Own
-
Inst Trans
-
ROA
-247%
ROE
-213%
ROC
-4.76%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6110.0-31950.0
52W High
-88.18%
52W Low
-38.22%
RSI
57
Rel Volume
0.19
Avg Volume
1.36M
Volume
255.23K
Perf Week
3.85%
Perf Month
16.87%
Perf Quarter
-
Perf Half Y
-17.49%
-
-
-
-
Beta
0.783508
-
-
Volatility
150.54%, 267.25%
Prev Close
0.67%
Price
3775
Change
-4.55%
Company Profile
- Volume Average 1.36M
- Market Capitalization 388.76B
- Employee 61
- CEO Mr. Seong-Jin Kim
- Headquarters Seoul,KR
- IPO Date 2019-12-19
-
Website
http://www.medpacto.com 
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.
